Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2025-12-24 @ 7:02 PM
NCT ID:
NCT00272857
Eligibility Criteria:
Inclusion Criteria:
* FA, as determined by a positive test for increased sensitivity to chromosomal breakage with mitomycin C or diepoxybutane
* FA complementation group A, as determined by somatic cell hybrids or molecular characterization; transduction of peripheral blood or bone marrow cells with the complementation group of specific retrovirus used in this study must demonstrate correction of mitomycin C sensitivity or cell cycle arrest
* Weighs at least 7.5 kg
* Normal cytogenetics on bone marrow within 3 months of study entry
* A minimum of 2 x 10(6) CD34+ cells/kg after CD34+ selection of the harvested bone marrow or mobilized peripheral blood product must be available to proceed with thaw (if cryopreserved) and transduction
* Human leukocyte antigen (HLA) typing with initial donor limited search results that indicate a potentially acceptable matched unrelated donor in the National Marrow Donor Program database
Exclusion Criteria:
* Cancer
* Clonal cytogenetic abnormality on bone marrow or peripheral blood karyotype within 3 months of study entry
* Myelodysplastic syndrome based on the FAB classification including:
1. Refractory anemia with ringed sideroblasts (RARS)
2. Refractory anemia with excess blasts (RAEB)
3. RAEB in transformation (RAEB-T)
4. Chronic myelomonocytic leukemia (CMML) (myelodysplastic changes in greater than two cell lines, refractory anemia alone, or aplastic anemia with dysplastic changes are permitted)
* Positive baseline screening result for both of the following:
1. Detection of Fanconi A proviral sequences by polymerase chain reaction (PCR) analysis
2. Detection of replication competent retrovirus by repeat testing by PCR of gibbon ape leukemia virus (GALV) envelope sequence or a positive S+L- assay
* Pregnant or breastfeeding; women of childbearing potential who are enrolled will be advised that the drug may cause birth defects and will be required to use an acceptable form of contraception
* Concurrent enrollment in any other study using an investigational agent, excluding androgens and thyroxine
* Physical or emotional status that would prevent informed consent, protocol compliance, or adequate follow-up with participant or legal guardian
* Participants for whom an acceptable HLA identical matched sibling donor (HLA A, B, DRB1; 6/6 match) has been identified (HLA typing of normal siblings must be documented)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
1 Year
Maximum Age:
35 Years
Study:
NCT00272857
Study Brief:
Protocol Section:
NCT00272857